<DOC>
	<DOCNO>NCT00086203</DOCNO>
	<brief_summary>The objective study assess efficacy safety talabostat rituximab patient advance CLL fail respond , progress follow prior response , fludarabine regimen .</brief_summary>
	<brief_title>Study Talabostat Rituximab Advanced Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description>Completion date provide represent completion date grant per OOPD record</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>INCLUSION CRITERIA : Men woman ≥18 year age Histopathologically confirm diagnosis BCLL express surface CD20 detectable intensity Rai Stage III IV . Rai Stages I II massive progressive lymphadenopathy hepatosplenomegaly . Primary resistance fludarabine regimen ( PR CR ) progressive disease within 1 year prior response ECOG performance status 0 , 1 , 2 Written inform consent EXCLUSION CRITERIA : Therapy CLL within 4 week Study Day 1 ( include chemotherapy , radiation , immunotherapy , cytokine biologic [ exception hematopoietic growth factor ] ) . Patients must recover adverse effect prior therapy . Known primary secondary malignancy central nervous system Any malignancy within 5 year immediately prior first dose study medication exception basal cell nonmetastatic squamous cell carcinoma skin , carcinoma insitu cervix Serum creatinine &gt; 2.0mg/dL ( &gt; 176 micromol/L ) AST ALT ≥3 x upper limit normal ( ULN ) Total bilirubin ≥1.5 x ULN ( unless secondary Gilbert 's ) Positive serology hepatitis B ( HBsAg ) hepatitis C ( antiHCV antibody ) Known positivity HIV Prior organ allograft Concurrent comorbid medical condition , opinion investigator , preclude safe delivery experimental treatment Pregnant nursing woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2006</verification_date>
</DOC>